Janet W. Dawson
Basel, BS 4002, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement.
Journal: Journal of medicinal chemistry
Published: October 15, 2025
A cereblon-based glue degrader of NEK7 regulates NLRP3 inflammasome in a context-dependent manner.
Journal: Cell chemical biology
Published: November 12, 2024
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 04, 2024
Degenerative joint disease induced by repeated intra-articular injections of monosodium urate crystals in rats as investigated by translational imaging.
Journal: Scientific reports
Published: July 28, 2021
Nonhematopoietic IRAK1 drives arthritis via neutrophil chemoattractants.
Journal: JCI insight
Published: March 22, 2021
Cantharidin-Induced Skin Blister as an In Vivo Model of Inflammation.
Journal: Current protocols
Published: February 18, 2021
Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase.
Journal: Journal of medicinal chemistry
Published: February 16, 2021
Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration.
Journal: The European physical journal. C, Particles and fields
Published: November 10, 2020
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Journal: Journal of medicinal chemistry
Published: February 22, 2020
Targeting interleukin-4 to the arthritic joint.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 24, 2019
Structure-Based and Property-Driven Optimization of N-Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors.
Journal: Journal of medicinal chemistry
Published: November 16, 2019
Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
Journal: ACS medicinal chemistry letters
Published: July 15, 2019
Last Updated: 09/26/2026